EMA developing principles on when to 'go broader or narrower' in indication wording
This article was originally published in SRA
Executive Summary
The European Medicines Agency is developing general principles on the wording that drug makers may apply to indicate in which populations their drugs can be used. The "indication wording" initiative will particularly focus on when the population may be broader or narrower compared to the study population investigated in the clinical trials supporting the marketing authorization application for the drug1.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.